Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

BioArctic, Audiocast, Q2'25

By Inderes8/28/2025, 7:30 AM
BioArctic

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Gunilla Osswald
00:01 - 09:57

Thank you. Good morning and welcome to BioArctic AB. Presentation for the second quarter of 2025. BioArctic AB is now entering a new era. It's an era of profitable growth. And I think it's signified by yet another strong quarter. And a lot of activities throughout the different parts of the business. We see increasing Leqembi royalties. And we are very pleased with the new partnership with Novartis. It's the third partnership utilizing our BrainTransporter technology, and it's the first of its kind. And I'll talk more about that in today's presentation. Next slide please. BioArctic AB is listed on Nasdaq Stockholm Large Cap. And this is our disclaimer. Next slide please. I'm Gunilla Osswald and I'm the CEO of BioArctic AB. And today I will share the presentation with our CFO Anders Martin-Löf. And also with our Chief R&D Officer, Johanna Fälting, and our Chief Commercial Officer, Anna-Kaija Grönblad. Next slide please. I will start our presentation and I will be giving some key highlights. Next slide please. But before I do that, I just want to provide a high-level introduction to BioArctic AB. If we have any new listeners today, BioArctic AB is among the world-leading innovators in precision neurology. We have two different platforms. The first aspect is the innovation, generation, and development of highly selective antibodies that target aggregated, misfolded forms of toxic proteins like Lecanemab, Leqembi, and Exidavnemab. The second part is utilizing our BrainTransporter platform in innovative ways in order to deliver their antibodies and different modalities more effectively into the brain. In today's presentation, we will talk more about both selective antibodies like Leqembi and Exidavnemab, as well as the BrainTransporter technology, which we have utilized now for all our internal targets. And it's also now being used for external projects. And an example of that is the recently signed deal with Novartis. Next slide please. During the second quarter this year, we held our first Capital Markets Day. And there, I presented our ambitions for 2030. And we have already started to deliver on our ambitions. And I'll just go through them briefly. The first one is for Leqembi to be established as a treatment for Alzheimer's disease. The second one is a balanced and broader pipeline with projects in all stages of development. And the third one is additional successful global partnerships. And this is an area in which I enjoy and engage heavily. And the fourth one is, of course, also very important: to be profitable with recurring dividends. And Anders will return to this later in the presentation. Next slide please. So as I said, we have already started to deliver on our 2030 ambitions. And I will tell you how. If we start with Leqembi, it's well on its way to becoming an established treatment for Alzheimer's disease. Thanks to our partner Eisai and their great work, Leqembi is now approved in nearly 50 countries and also in Europe since the 15th of April this year. The European launch has been initiated this week with Austria starting this Monday, and Germany is preparing for the launch next Monday, on the 1st of September. Our partner Eisai has submitted the dossier in the four Nordic countries: Sweden, Finland, Denmark, and Norway, and at the world's largest Alzheimer's Congress, which was held in Toronto in July. Um, more encouraging data was presented. It was a great Congress with about 10,000 participants, with a lot of positivity in the field. There were many presentations on Leqembi, including long-term data over four years, showing increased benefit over time. Eisai also presented data on the subcutaneous administration of Leqembi, and this supports a great opportunity for patients to administer it themselves. It can be an easier way by using an auto-injector to receive the injection at home, for example. I think it was a very positive meeting, with a lot of hope for patients. There was also reporting on blood-based biomarkers and their great progress, as well as the launch of guidelines for them. The second aspect I want to talk about is the pipeline, and we are growing with further projects in development, and the projects are progressing well. An example of that is Exidavnemab, our alpha antibody, which is currently in Phase 2A, and during the second quarter, it passed its safety evaluation and has now progressed into the next part of the study with higher doses. And that is now, um, both in Parkinson's patients and in MSA patients. And so we are broadening indications for Exidavnemab. We're also very happy that we got orphan drug designation in both the US and EU for Exidavnemab. With regard to the MSA indication. We have also broadened our portfolio, linked to the new deal with Novartis, with a new neurodegeneration project utilizing BrainTransporter, which of course is their project. However, we are providing support. Then we come to partnerships, and here we stated that we should pursue additional successful global partnerships. And as I said, I'm very happy with the new collaboration with Novartis regarding an undisclosed target for neurodegenerative diseases. We will re-engineer their antibody to include our BrainTransporter technology, enabling better penetration into the brain. Our BrainTransporter collaboration that we had previously and which is ongoing with Eisai on BAN2802 is progressing according to plan, and the tech transfer of BAN2803 to Bristol Myers Squibb is on track. It's also great to see that we have continued strong interest in our BrainTransporter technology. Our financials are strong and we are highly profitable with record royalties, as well as the European regulatory milestone from Eisai during the second quarter. And the new agreement with Novartis will bring an upfront payment of 30 million USD to BioArctic AB. Next slide please. I'll just talk a little bit also about the agreement with Novartis, which is our third agreement to include our BrainTransporter technology, and it is the first one where another company brings their cargo antibody for us to re-engineer into a new antibody to introduce our BrainTransporter technology. I think this agreement shows that BioArctic AB is now also a platform company. Importantly, the BrainTransporter platform is BioArctic AB's proprietary technology, and in our business model, we are making deals linked to different targets while keeping the platform to ourselves. The Novartis agreement encompasses one undisclosed target for neurodegenerative disorders, and it is distinctly different from our other collaborations and targets. The Novartis agreement starts with the generation and evaluation phase, after which Novartis has the option for a full license. BioArctic AB is entitled to 30 million USD upfront, and the total deal value of this agreement is up to 802 million USD, plus mid-single digit royalties if the product reaches the market. The three agreements we have so far with the BrainTransporter technology platform are all with antibodies. But I also want to mention that we are investing and expanding our efforts into other modalities as well, where we also would like to see better brain penetration in order to have better efficacy. We have further business development discussions ongoing, and we aim to establish more collaborations in the future. But we have to realize that these kinds of discussions take time. Next slide please. So by that I will now hand over to our chief R&D officer, Johanna Fälting for an update on R&D.

Johanna Fälting
09:58 - 18:03

Thank you so much, Gunilla. Next slide please. So starting with an overview of our R&D portfolio, we have two world-leading platforms as described in Precision Neurology with cross-program synergies. First, we have our antibody projects with highly selective antibodies targeting aggregated forms of toxic proteins intended for the treatment of severe neurodegenerative diseases with high unmet medical need. And then we have projects based on our BrainTransporter platform that deliver biopharmaceuticals more effectively into the brain. And for those of you familiar with our portfolio, you will now notice a new project in the portfolio, the ND-BT8825. And that is the Novartis collaboration on an undisclosed target in neurodegeneration, combining the Novartis antibody with the BioArctic AB BrainTransporter technology. We're very happy now to have three collaborations in the portfolio with distinct and different targets. And importantly, like Gunilla said, the BrainTransporter technology is proprietary to BioArctic AB and it will have the possibility to generate more collaborations in the future. So to summarize the portfolio, our R&D portfolio combines fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects and technology platforms with significant market and outlicensing opportunities. Next slide please. So a major challenge working with brain disorders is that only a small fraction of the antibody or the biopharmaceutical administered via the blood enters the brain. So the aim with our BrainTransporter technology is to improve brain exposure, allowing for lower doses, improved dosing convenience, reduced manufacturing costs, and potentially also improved efficacy and better brain distribution. So we have a unique approach targeting active brain transport via the transferrin receptor. And this platform has been clinically validated in non-human primates, showing an improved brain exposure of up to 70-fold without affecting reticulocytes, which is a safety concern with this approach. And what we are doing now is currently working with different modalities, as Gunilla described, such as antibodies and enzymes. But we are evolving the technology also to other modalities such as proteins, peptides, or even antisense. And this will also bring new modes of actions and expand the target space in the brain. So the BrainTransporter technology platform unlocks enormous potential not only for internal projects, but also for external opportunities. And as mentioned, we see a high external interest in our platform. Next slide please. So Exidavnemab is an antibody that selectively targets pathological alpha-synuclein aggregates while sparing the physiological monomers. Exidavnemab is in phase 2a in the EXIST study. And this is a study with the primary endpoint being the safety and tolerability of Exidavnemab. But we are, of course, also exploring a wide range of biomarkers, including biochemical, digital, and imaging biomarkers. And this is a very innovative study, I would say, and unique in its approach of including the right patients in the study. And we do this by a smell test and also a CSF seeding amplification assay to ensure that the. The patients included in the study have the correct diagnosis and have the alpha-synuclein pathology that we are targeting. In June, we had a safety review of cohort one with Parkinson's patients, supporting progression into the higher dose. And cohort two is now intended to be initiated in both Parkinson's and multiple system atrophy. So Exidavnemab is progressing well in phase 2a, and the study results are expected in mid-2026 as mentioned. Exidavnemab has reached orphan drug designation for MSA, which is a rare progressive neurodegenerative disorder in both the US and the EU. And following the EXIST study, we see several possibilities for further development in different synucleinopathies such as Parkinson's, MSA, or DLB. And we are currently evaluating and preparing for the next phase of development. Next slide please. And as I mentioned, everything that we have seen coming out from the AAIC (Alzheimer’s Association International Conference) meeting in Toronto this summer has been very positive, especially when looking at the Leqembi data. Eisai presented new data from the Phase 3 open-label extension study, and new data from patients treated with Leqembi for up to 48 months are shown on this slide. And to start with, the efficacy and treatment effects continue to expand compared to the natural course of the disease, as shown by ADNI or BioFINDER data. And another way of describing the efficacy is to talk about time saved or the time that you stay in an earlier stage of the disease. In this analysis, the time saved is up to 13 months after 48 months of treatment. And also in terms of safety. Long-term safety profile continues to be in line with previous data. So next slide please. And. So in addition to the full Clarity AD study results, a subgroup analysis has also been done. And I would like to highlight this one in patients treated with Lecanemab and patients that have a low tau. So this subgroup is likely to have an earlier stage of the disease. And they seem to benefit even more from the treatment. Looking at the CDR sum of boxes, a large percentage of patients are being stable or even improving after 48 months. And this is, of course, very, very exciting data, but it's also a smaller study. We have to be mindful that this is a small population, but it shows the importance of starting treatment early on, and we are really looking forward to the results from the AHEAD study testing Leqembi in earlier Alzheimer's disease patients. Study results are testing Leqembi in earlier Alzheimer's disease patients. So next slide please. So in addition to the presented long-term efficacy and safety data of Lecanemab. Important presentations during the Congress covered real-world evidence data from Leqembi being used in clinical practice. And these data confirm the clarity and Phase 3 data. And it's very reassuring that the real-world evidence data aligns with the clinical study, both regarding safety and efficacy. Also, Eisai presented encouraging data on the subcutaneous autoinjector maintenance treatment. And of course, a more convenient subcutaneous dosing will allow patients to easily be treated at home, enabling continued treatment without visiting infusion centers. And I will talk more about this. And also, in addition to the Eisai presentations at AAIC (Alzheimer's Association International Conference), new guidelines for blood biomarkers were presented, and Anna will talk more about this as well. So taken together, all of the data presented will help to expand Leqembi usage. Next slide please. And I now will hand over to our Chief Commercial Officer, Anna-Kaija Grönblad, for a commercial update.

Anna-Kaija Grönblad
18:04 - 25:13

Well thank you, Johanna. Well, as mentioned earlier, Leqembi, as you can see, has now been approved by 17 health authorities globally, covering 49 countries, with the latest approvals since the last quarterly report being in Thailand. So Saudi Arabia, Qatar, Kuwait, and Bahrain. Meanwhile, in the US, we are eagerly awaiting the FDA decision any day now on the subcutaneous autoinjector for maintenance dosing. And soon, there will be more comments on the actual sales. But in short, Leqembi is growing steadily in different regions and markets. And in the US. We can see that the usage of both blood biomarker tests and PET and CSF testing is increasing, indicating that more patients are being investigated for Alzheimer's disease. As for the European Union, after the European Commission approval in mid-April, it's really exciting news now that Austria launched earlier this week on Monday and that Germany is planning to launch next Monday. Uh, these are usually the early launch countries where there will be a gradual rollout of the expected launches in the European Union throughout 2026 and into 2027. Following the regulatory requirements and their national pricing and reimbursement processes in France and Spain. On the other hand, there is an opportunity to provide Leqembi sooner through an early access program, and this will probably be in place in the last quarter of this year. As Gunilla mentioned, in the Nordics. Eisai has submitted the dossiers to the authorities in four of the Nordic countries for the health technology assessment, which is the start of the whole pricing and reimbursement process. And there are no fixed timelines for these processes. But we are aiming to launch in the Nordics next year, in 2026. Next, please. Next slide please. So, um, I would like to come back to what Johanna referred to earlier regarding the developments in this field presented at the AAIC (Alzheimer’s Association International Conference) in July, both in regards to blood-based biomarkers and also Leqembi's competitive edge and growth opportunities thanks to the subcutaneous auto injector. Firstly, I think the fact that we now have both clinical practice guidelines from the Alzheimer's Association in place in the US, and the first blood test approved by the FDA in May, which was the Fujirebio test, is remarkable. And there are probably more to come soon. This clearly offers a simplified diagnosis pathway in the future. The usage of PET and CSF will probably decrease, which also means lower costs and infrastructure needs for healthcare. As an example, here in Sweden, the Sahlgrenska University Hospital offers clinics the possibility to analyze blood samples for the Fosfato 217 biomarker. Since July this year. This will clearly simplify, as I said, the diagnostic flow, since it will be easier to evaluate which patients need to be investigated further, while other patients can have the results much quicker if their cognitive issues are not due to Alzheimer's disease. In the future, it can also be used in primary care as a triaging tool, detecting patients earlier, improving referrals, i.e. Making sure that the right patients are referred to the specialist clinics. Secondly, I already mentioned the subcutaneous auto injector. This also offers a choice for both the patient and the healthcare professional to select the treatment option best suited for that specific patient. Not only could it provide freedom for the individual to self-inject at home, but the use of the auto-injector will also free up infusion capacity at the hospital and reduce costs for payers. Eisai expects that the potential approval of the subcutaneous initiation treatment could come in the first half of 2026. And finally, the four-year study mentioned ahead. And finally, the four-year study previously mentioned. With more than 1,400 people with pre-symptomatic Alzheimer's disease, the study was fully recruited in October last year and offers new opportunities both for the science to evolve and for the potential growth of Leqembi. So it's really exciting times ahead. So next slide. So, just a few words on the Nordics, where we have been gradually building a team of very experienced, knowledgeable, and, I would say, very motivated pharma professionals. We are about 20 people in the commercial operations team at BioArctic AB, working very closely with our colleagues at Eisai. And since the European Commission approval, we have onboarded some additional field-based people who can help prepare the healthcare system for the upcoming launch. We have supported ASA in the HTA submissions and will continue to do so in the upcoming price negotiations. Our objective is to help optimize the early patient journey and the infrastructure, and educate on the value that Leqembi brings. We have engaged in several collaborations with healthcare, mentioning only a couple here such as the EU Prominent Project and the Relayed Study in Sweden. We can now also promote Leqembi proactively in three of the four Nordic countries, and we experience a big interest from the healthcare professionals in learning more about the field and Leqembi. Next slide. So just in my final slide, I have selected a couple of additional examples of initiatives that we have prepared to roll out in the Nordics to support our launch. On the left-hand side, you can see the HCP web portal called Campus Alzheimer, which will be launched in Sweden in the coming week. And in the coming months in the rest of the Nordics, the educational need is significant, and we have strived to create a hub where Nordic healthcare professionals can find all the relevant and updated information about the diagnosis and treatment of Alzheimer's, new research findings, training opportunities, upcoming events, etc. Also, on the right-hand side, you can see the invitation to what is expected to be an annual high-quality Nordic educational event in Stockholm happening only in one week's time. This has been organized together with an external Scientific Steering Committee who has put together an excellent program. So all in all, we are very excited to enter this new chapter in Alzheimer's disease. With the expansion of Leqembi globally and the launch of Leqembi in the Nordics. And with that, I hand over to Andrea for a financial summary.

Anders Martin-Löf
25:13 - 33:58

Thank you, Andrea. If I start with the Leqembi development, we see very strong growth during the second quarter. Uh, the global sales increased to ¥23.1 billion, or between $106 million and $160 million, which represents a 57% increase quarter over quarter, or roughly a fourfold increase from the same quarter last year. This is partly due to a stocking effect in China, where sales were ¥7.7 billion, or $52 million, which is a 300% increase from the first quarter. And this is due to the threat of tariffs, which meant that large inventories were being built up in China during the quarter. Uh, but as I calculated, if you remove this stocking effect, the growth in China would still have been 24%, or global growth would have been 20% if you remove that one-time effect. So all in all, the underlying growth is still very strong. And it was further boosted by this one-time effect in China. And if you look at the different markets, I would say Japan is still the strongest market that has progressed the furthest in the implementation of Leqembi treatment. They are now well into the demand expansion phase, with sales of ¥5.5 billion, or $38 million. That's a 23% increase from the first quarter. And here they're already starting the second disease awareness campaign for mild cognitive impairment, which is the earliest phase where you can use Leqembi. And this is the largest area where we believe growth can be seen in the future. And they have also been very successful in setting up a large network of 1,500 follow-up facilities that are collaborating with the sites where the patients receive their initial treatment, allowing them to be transferred to these follow-up facilities after approximately six months of treatment. And this is a pattern that Eisai is now replicating in the US, where we're also seeing solid growth. Even though there is more competition in the US where Eli Lilly is very active, sales of Leqembi in the US were ¥9.1 billion, or $63 million in the quarter. That's a 14% increase from the first quarter. And there were some currency headwinds. So at constant currency rates, the increase would have been 20%. And here the market is growing fast. There is competition from Lilly, but Lilly is also helping to build the market, and the market growth is now expected to continue. And it will be further boosted by the initiation of the usage of blood-based biomarkers for diagnosis and not just for triaging. So, we do expect to see continued market growth boosted by this. And here, Eisai has now launched a targeted direct-to-consumer campaign. Uh, and they will spend more efforts on involving primary care in the second half of this year, roughly what they have been doing in Japan quite successfully. And this will, of course, be supported by the approval of the subcutaneous version, which makes it much easier for the patients to take the treatment at home. And all in all, this means that the primary care segment will be much more active in the whole chain. It will also be interesting to see what will happen in the EU. As I mentioned, Leqembi is now launched in the EU for the first time. However, it will take some time before we see a significant impact of this in the royalties, as it takes a couple of quarters to establish the treatment, as we have seen in the US and Japan. But, of course, it's very encouraging that we're now finally on the way to you as well. If we then turn to the forecast, we think that this very positive development we see now means that Leqembi is fully on track to reach the forecast of ¥76.5 billion in the fiscal year of 2025. And this is a forecast that they have issued. Uh, and it covers the second quarter of 2025 until the first quarter of 2026. Uh, and what we can see now is that they are above plan in several markets. For example, if we look at China, as you can see here, it is expected to sell ¥9.5 billion in total in the fiscal year, and the sales in the first quarter of the fiscal year was ¥7.7 billion. So they just need an additional ¥1.8 billion in the coming three quarters to reach the forecast. And it's the same if you look at Japan and the US and calculate what growth they need to reach the forecast. It's roughly 6% in both markets. And they're currently growing at roughly 20% in both markets. And there is really nothing that suggests growth will decrease significantly. Eisai even stated that July is the first month of this quarter that we are in right now. What was the strongest month they have ever seen? So, all in all, we think there is a very high likelihood that Leqembi will beat the forecast when we close the year. If we then turn to our own financial figures. Uh, our second-quarter revenues were 392 million Swedish, which is quite a significant increase from 50 million Swedish in the same quarter last year. And this is then, of course, due to the milestone payment that we received of €20 million. But the recurring revenues are increasing and will continue to increase. As you see now, the royalty was 162 million in the second quarter. Co-promotion is still not that substantial. But as activities get going during next year, we expect to see an increase in Co-promotion revenues as well. Um, the Novartis upfront payment that we talked about earlier of $30 million, uh, will not be recorded fully this year. Uh, it will be recorded over the entire research collaboration phase of that project. And I would estimate that roughly 20% of the upfront payment will be recorded during this year. If we then turn to our expenses, you see that our operating expenses increased to 193 million from 121 million last year, with roughly 32 million of that being due to currency effects. So the underlying operating costs were roughly 161 million, compared to 120 one year ago. And, uh, we spend heavily on R&D. And so, 70% of our operating expenses are allocated to R&D for the remainder of the year. We do expect to see an increase compared to last year. Uh, I have previously stated that we expect operating costs of 2025 to be roughly 60 to 80% higher than 2024. We now see that it's going to be lower than that. So now we estimate that it's going to be roughly 50 to 70% higher than the cost of last year. If we then turn to the operating profit on the right hand side, you see there was 179 million for the second quarter. Uh, it's a decline from the first quarter, but that was then heavily impacted by the $100 million upfront payment that was fully reported in the first quarter. I should remind you that the second half of the year will most likely be less profitable than the first half of the year, but we do expect that the operating profit for the full year will be above 1 billion Swedish crowns. On the next slide, you see our net profit on the left-hand side. The net profit was 97 million Swedish, which is roughly 82 million less than the operating profit. In that, it is then explained by the negative financial net due to currency effects and accrued tax of 75 million. And in the middle graph, you see our whopping cash flow of more than 1.1 billion plus in one quarter. That would be hard to beat for the coming quarter. But that's, of course, explained by the 100 million received from BMS and the 20 million retrieved from Eisai. Uh, during the quarter. So, we have a very, very strong cash position, approximately 1.9 billion at the end of the second quarter. And that's the equivalent of roughly three years of underlying costs currently. So we have a very strong financial position, and it will continue to strengthen during the last quarters of the year since we will receive the $30 million from Novartis during the fourth quarter. So I expect to end the quarter with more than 2 billion Swedish cash and cash equivalents. With that, I hand back to Gunilla for some closing remarks.

Gunilla Osswald
33:59 - 37:24

Thank you so much, Anders. So we're coming towards the end of today's presentation. Uh, I'll just review some of the news flow and make some closing remarks. So next slide please. We just informed about the initiation of the Leqembi launch in Europe, which started in Austria this week, with plans for Germany at the beginning of next week. We are eagerly waiting for the response from the FDA regarding the subcutaneous autoinjector for maintenance dosing in the US, where the due date is 31st of August. Our partner Eisai is preparing for a US filing for induction dosing using the subcutaneous autoinjector soon thereafter, and we are hopeful for approval in the first half of next year. I think the subcutaneous autoinjector will be an important additional treatment option, making administration much more convenient for patients and less costly for society. We are also expecting further regulatory responses on lecanemab. The next countries for commercialization, with early access in the EU, are expected to be France and Spain, and we are looking forward to further European launches next year, including the Nordics, which of course is very exciting for us at BioArctic AB. During the first half of next year, we also expect the Exidavnemab phase three study to be concluded and a decision on next steps for development. And there we see several different opportunities, as you described. So in summary, we have a lot of exciting things ahead of us. And next slide please. So some key takeaways from today's presentation are that BioArctic AB has now entered a new era, an era of profitable growth. And that is signified by yet another strong quarter. We see increasing Leqembi royalties, and we are very pleased with the new partnership with Novartis. We are starting to deliver on our 2030 ambitions, both with regard to Leqembi, which is well on track to become an established treatment in Alzheimer's disease. Where we have also seen further regulatory approvals, additional launches, and reassuring data. Both from long-term treatment and real-world data, and continuously increasing revenues. And the number of patients that we are helping on a global level continues to grow. The second part is Exidavnemab, which is progressing very well with the high-dose part of the phase 2 study being initiated in both Parkinson's disease and MSA patients. Our business development efforts continue to deliver, with a third BrainTransporter partnership agreement signed. And this is, as I said, the first of its kind, expanding BioArctic AB into being a platform company now. And the fourth part is that we have strong financials, with yet another highly profitable quarter featuring record royalties and cash flow. So I think that the future looks very bright for biotech, with great hopes for many patients. So next slide please. So by that, I say thank you so much for your attention. And we are happy to take some questions.

Operator
37:29 - 37:40

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad.

Viktor from Nordea
38:02 - 38:05

Viktor from Nordea. Go ahead. Your line is open.

Viktor from Nordea
38:08 - 39:21

Um, yes. And the fourth part is that we have strong financials with yet another highly profitable quarter, featuring record royalties and cash flow. Um, thank you for taking my questions. I have three from my side. And the fourth part is that we have strong financials with yet another highly profitable quarter, with record royalties and cash flow. Um, so, uh, maybe first on the Novartis deal. I just wanted to see if you could elaborate on how long you expect the evaluation of your BrainTransporter technology, together with the antibody from Novartis, to take before we could reach a stage when Novartis could exercise its option, and perhaps what kind of data they would be looking at, whether it's preclinical or if they need some kind of more advanced data. Um, secondly, with the one-time stocking in China that was announced for Leqembi in quarter two, I wonder if you've heard from your partners if this could lead to lower sales in China in Q3 or Q4, or have any other information on this. And just finally, I just noticed on your pipeline slide, um, that I didn't see BAN2401 in Down syndrome. Um, just wanted to understand if this has been dropped from your development program or, um, or if, um, yeah, if it was due to any kind of commercial evaluation or if it was driven by any data you generated. And the fourth part is that we have strong financials with yet another highly profitable quarter, marked by record royalties and cash flow.

Gunilla Osswald
39:23 - 39:53

Thank you so much, Viktor. Three great questions. So we start with the first one regarding the Novartis collaboration. So, that is the first part where we should generate the new asset and then do some evaluation work together with Novartis. And I think that period is preclinical, and it's about two years. Your second question with regard to Leqembi and China, I'd like to address that.

Anders Martin-Löf
39:53 - 40:13

And the fourth part is that we have strong financials with yet another highly profitable quarter with record royalties and cash flow. So, no, we don't have any specific details. Uh, but I think it is to be expected that sales will be significantly lower in the coming two quarters than they would have been without this stocking effect. At least that's a fair assumption, even though I don't have any full details to share.

Gunilla Osswald
40:15 - 40:41

And then your third question with regard to Lecanemab, or BAN2401, Lecanemab in Down syndrome. And it's definitely not dropped. It's just not on the slide anymore because we are not doing much work on it at the moment. But of course, Down syndrome is an important patient population that potentially also could benefit from Leqembi. So it's definitely still on the radar.

Viktor from Nordea
40:44 - 41:07

So, at least that's a fair assumption, even though I don't have any full details to share. So, at least that's a fair assumption, even though I don't have any full details to share. And just a quick follow-up on Novartis: when they exercise, or if they would exercise the option when data has been generated, could that trigger an additional upfront payment, or would it just enable Novartis to take over the rights of the program and then pay you milestones? Further out, there's an expectation for more developments.

Gunilla Osswald
41:09 - 41:35

So we're not disclosing details about the rest of the milestones, but I can say that there is a next milestone linked to when they exercise the full license deal. So, that is also a milestone at that stage. But I'm not disclosing how big that one is. But, um. Um, and then of course, it's a normal approach to handle the rest of the milestones, including development and commercial.

Viktor from Nordea
41:38 - 41:39

Okay. Thank you very much.

Gunilla Osswald
41:40 - 41:40

So, at least that's a fair assumption, even though I don't have any full details to share. Victor.

Viktor from Nordea
41:40 - 41:41

For me.

Operator
41:45 - 41:50

The next question comes from Joseph Hedden from WR Securities. Please go ahead.

Joseph Hedden from WR Securities
41:53 - 42:21

Good morning. Thanks for taking my questions. And congratulations on the Novartis deal. Um, just wanted to dig a little deeper into the deal. Um, is the target that Novartis is pursuing? Is that a target related to one indication, or could it potentially span several neurodegenerative indications? Um, and then could you say whether these are rare diseases or broader indications like Alzheimer's disease?

Gunilla Osswald
42:24 - 42:39

So, at least that's a fair assumption, even though I don't have any full details to share. I really can't disclose much about that program, but I can say I think it's a very interesting target that can potentially help many patients. And it can be several different indications, but I'm not going to reveal any details.

Joseph Hedden from WR Securities
42:43 - 43:01

Okay. Thank you. And then, just on the research collaboration agreement with Eisai where they have an option on a BrainTransporter candidate, is that still progressing well and perhaps on track for a decision from them in 2026? I think that was the initial target.

Gunilla Osswald
43:03 - 43:17

So our collaboration with Eisai is progressing really well according to plan, and that is with regard to BAN2401 that you're talking about. And I cannot comment exactly on the timelines there, but it's progressing according to the plan, and it all looks good.

Joseph Hedden from WR Securities
43:21 - 44:05

Okay. Thank you. And then just perhaps a question on the rare diseases portfolio where you're using BrainTransporter tech to look at candidates in ALS and Gaucher pre-clinically. Could you elaborate on the overarching strategy when considering these rare diseases? Will you take these candidates into the clinic yourself? Um, to, to kind of progress them a bit further down the line before looking for a licensing deal? Or, are these available for licensing straight away as has been your historical model? Apart from Exidavnemab at the moment. Thank you.

Gunilla Osswald
44:06 - 44:55

Thank you so much. Another good question, Joseph. So I think based on that, we now have a strong financial situation. We have all possibilities. So, I mean we could advance programs much further, potentially all the way to the market when we discuss rare diseases. Um, but we still have an open-door policy, so if we get a good deal proposal, we might partner. So, it's a great strength for biotech that we could partner. We don't have to partner so we can do what we think is best for the projects. And both of those, I think, are very, very exciting rare disease indications with huge opportunities for us to potentially drive them ourselves longer.

Joseph Hedden from WR Securities
45:00 - 45:03

Okay. Thanks very much and congrats again.

Gunilla Osswald
45:03 - 45:04

Thank you so much, Joseph.

Operator
45:08 - 45:13

The next question comes from Myrth Bain from Van Lanschot and Kempen. Please go ahead.

Unknown 1
45:15 - 45:56

Hello. I'm calling in for Louisa from Canva. First, congrats on the Novartis deal. I had a few questions regarding the Novartis deal. Do you expect from here onwards to establish more deals using the BrainTransporter tech also as an option deal, or more similar to the deal with Novartis? Secondly, could you remind me what the next steps are for Exidavnemab? And could you provide more color on what the differences are? What differentiates BioArctic AB's BrainTransporter from other similar technologies using the same transfer? BrainTransporter. Thank you very much.

Gunilla Osswald
45:57 - 47:43

Thank you for three great questions. So the first one, uh, regarding the BrainTransporter, this is our proprietary technology. And, uh, I think that we can foresee several different opportunities in the future. We could foresee more deals like the one we did with Novartis, whether another company comes with their assets and wants them to be re-engineered into a new asset which has better brain penetration. So I think that's one possibility in our business model. We are also working on other modalities, and we are open to discussions for collaborating with others on other modalities as well. And, uh, we have then combined the BrainTransporter with all our internal targets, and that could potentially be deals more like the one with Bristol Myers Squibb, uh, where it was combined with one of our internal programs. So I think the beauty with BioArctic's portfolio and the approach that we're working on is that we can drive ourselves or partner with our own assets. We can also, now, since we are a platform company, work with other companies' assets and improve them. Or we can pursue further development of the BrainTransporter technology ourselves or together with others. So we have a lot of opportunities and great possibilities that I think will be significant for the future, both with our own therapeutic targets and with our BrainTransporter technology. And maybe Johanna, you want to allude a little bit to what's different with our technology versus others?

Johanna Fälting
47:43 - 49:09

Yeah, absolutely. Thank you. So I think that, yes, we are working with the transferrin receptor, and many companies are pursuing the same target for active transport into the brain. And I think that's great because this target actually has clinical validation from the Roche Brain Shuttle program. What is unique with our approach is that we have done extensive screening, and we have a lot of structural data that has allowed us to identify a unique epitope on the transferrin receptor that is different from other companies, as far as we understand it. And this epitope and the binding site then enable us to not interfere with the normal function and the normal transport function of the transferrin receptor. And also it's positioning our antibody, a very therapeutic antibody, close to the cell membrane. And that is something that is very important. We believe from a safety perspective in interacting and not interacting with Reticulocytes. That has been reported as a potential side effect with these kinds of approaches. So I think that we have a unique way of interacting with the transferrin receptor, enabling us to have a better safety profile. And we have seen great data in the non-human primate study with an almost 70-fold increase in brain exposure. So we think that we have a truly unique approach in that sense.

Gunilla Osswald
49:10 - 49:16

And that is something that is very important. Johanna, maybe you want to talk also about the Exidavnemab question. And that is something that is very important.

Johanna Fälting
49:16 - 49:57

So where are we heading? Yeah. So the Exidavnemab, of course, I mean, we are now eager to think about what's going to be the next step for Exidavnemab. There are several different opportunities there in terms of MSA, Parkinson's, or DLB. And we are, of course, looking into how the competitive world is evolving. And we know we're, of course, encouraged also by the target that Roche has now pursued into phase three. And Lundbeck has advanced their compound into phase three for MSA, while Roche is targeting Parkinson's. In Parkinson's. We see many opportunities there for further development.

Gunilla Osswald
49:59 - 50:00

I hope that answered your question so much.

Unknown 1
50:00 - 50:04

I hope that answered your question. And that is something that is very important. And that is something that is very important.

Operator
50:07 - 50:11

The next question comes from Natalia Webster from RBC. Please go ahead.

Natalia Webster from RBC
50:14 - 51:28

Hi. Thanks for taking my questions. I have three, please. The first two are just on Leqembi. The first one is fairly broad. Just curious to hear a bit more about the progress you're seeing in infusion capacity in the US, and the impact you've observed from recently approved blood-based biomarkers. Secondly, if you're able to comment a bit more about your expectations for the European launch. Appreciate it's early days, and you said it'll take a couple of quarters to see impact. But curious if you're expecting to encounter some of the challenges that you saw in the US around capacity. And if there's anything you're doing at the moment that can help mitigate that. Thirdly, just on profitability, you've maintained your long-term ambition for sustainable profitability and recurring dividends. This year should be helped by milestones, but I just wanted to check that you're still confident on reaching sustainable profitability from 2026 onwards. And also, if you're able to comment on when you may expect to start paying dividends. Thank you.

Gunilla Osswald
51:30 - 51:34

Yeah, thank you so much. I think we start with Anna and Leqembi. Questions, please.

Anna-Kaija Grönblad
51:34 - 52:58

Yes. If I remember your questions right, it was about the US and the development of the growth related also to the subcutaneous. And what Eisai has communicated is that we can expect a kind of increase of Leqembi starting at the beginning of next year, thanks to a potential approval of the subcutaneous autoinjector for the maintenance treatment. So it will take some time. Uh, I guess it will take some time for the growth to come through the system. Um, and I think also mentioning the different data we see from lab companies, it's encouraging to see that, as I mentioned, the usage of different blood-based biomarkers, but also patients' CSF testing are increasing, which would indicate that the growth is really starting to expand for the usage of Leqembi. And we haven't seen any, let's say, signs of decreasing growth also after launching. So it seems to be beneficial that we have two companies driving the need to change the infrastructure and streamline the patient journey. So I think it's encouraging to see that growth continue. We expect it to continue even more at the beginning of next year.

Gunilla Osswald
52:58 - 52:59

And the blood-based biomarkers.

Anna-Kaija Grönblad
52:59 - 54:20

Yes. And of course, the blood-based biomarkers have been mentioned many times during the call already today. I mean, this has been talked about for many years, but now it's really happening. So, so this is really encouraging. But it will take time when it comes to the European launches, as I mentioned. There's a regulatory requirement to implement this controlled access program. This needs to be done at a national level. And also, the different pricing and reimbursement processes vary across European countries. So, I think you will see the launches roll out gradually, mainly during next year. But we know that there are quite a few centers already in France, for instance, ready to initiate Leqembi usage through this early access program. So it will take some time, and we will probably see the same kind of infrastructure challenges as in the US. And we've heard from our colleagues in Austria about how they have worked on this and what is key. A key takeaway is that you really have to be close to each hospital clinic, as the challenges might be different from one hospital to another.

Gunilla Osswald
54:23 - 54:27

And then we continue to discuss profitability and those questions.

Anders Martin-Löf
54:28 - 55:09

Sure. Yeah. So, we have mentioned earlier that we expect to be profitable from this year onwards based on the royalty revenues, especially from next year. And no, we haven't changed anything; we still expect to be profitable from 2026 onwards. As for dividends, uh, I can't really answer that. It's a bit early to call. Uh, I said at the Capital Markets Day that, uh, I think it's likely to happen within 1 or 2 years, but it really depends on what happens with Leqembi. And I do expect that our board would like to see that we're profitable on a sustainable level based on Leqembi royalties before that happens.

Natalia Webster from RBC
55:12 - 55:13

So it will take some time, and we will probably see the same kind of infrastructure challenges as in the US. So it will take some time and we will probably see the same kind of infrastructure challenges as in the US.

Operator
55:19 - 55:23

The next question comes from Rajan Sharma from Goldman Sachs. Please go ahead.

Rajan Sharma from Goldman Sachs
55:26 - 56:17

Hi. Thanks for taking my questions. Um, I also had one on the Novartis deal. So Novartis is also collaborating with Saranacs on a brain delivery platform, and I'm just wanting to understand how your technology compares to Saranacs and whether the target you're working on is different from that being explored by Novartis with Saranacs. Um, and then just a couple on Leqembi. So firstly, just on the Nordic launch. Um, could you provide just a little bit more color on timing there? Is that likely to be in the first quarter of next year, or is it more likely at some point during the first half? Um, and then the other one was just on subcutaneous Leqembi. Um, what's your expectation for approval in Europe? And do you expect that to influence some of the reimbursement decisions and discussions that you're having? Thank you.

Gunilla Osswald
56:19 - 56:32

And great questions. The first one will have a very short answer, and I will not comment on Novartis; that's for them to comment on their other collaborations. And then we turn to Leqembi and the Nordics.

Anna-Kaija Grönblad
56:33 - 56:51

Yes. I mean, as I mentioned, there are no fixed timelines for these kinds of processes. So we are expecting launches throughout 2026. Uh, so it's, it's, I can't kind of finalize the exact details at the moment. It would be a guess from my side exactly when this will happen. So 2026.

Gunilla Osswald
56:51 - 56:54

2026 and subcutaneous in Europe?

Anna-Kaija Grönblad
56:54 - 57:02

Yes. So, I mean, we're hoping that there will be a decision from Eisai to also launch the subcutaneous version in Europe. But we haven't heard anything yet on that.

Gunilla Osswald
57:02 - 57:04

And for the authorities to review, of course.

Anna-Kaija Grönblad
57:04 - 57:05

To review, of course.

Gunilla Osswald
57:06 - 57:15

Um. So, not much more we can say there. So, um, next question please.

Unknown 2
57:19 - 57:49

If Roger didn't have any more questions, we have a few that have been written and sent in. So I'll read them and then maybe we'll help direct. Who, um, who should take them? So, a couple of questions from Frederick at Redeye. Um, and he's asking, you know, in relation to the deal with Novartis, I guess, should we expect more option or evaluation agreements for the BrainTransporter platform? You know. When it comes to using external drug candidates, I think you've touched on that already. Gunilla.

Gunilla Osswald
57:49 - 58:07

Yes. And the answer is yes. But we cannot say anything about timing. I mean, you should be aware. I mean, these kinds of discussions take time, so. But definitely, we have a lot of possibilities for the BrainTransporter in the future in different ways.

Anders Martin-Löf
58:07 - 58:07

Yes.

Unknown 2
58:08 - 58:25

Then maybe a couple for Anders. Um, the stockpiling effect that we saw in China, have we had any indications of anything similar happening again, or is it likely just a Q2 thing? And then secondly, if you can talk a bit about the tax post in more detail.

Anders Martin-Löf
58:26 - 59:04

Um, well, if nothing extreme happens, I don't expect any similar effects in the future. However, there may be new initiatives coming from the US government that will have an impact like this. So. So if that happens, of course, I can't promise that it won't have an effect on this. Uh, as for the tax recorded, well, it's based on an estimate of the profit for the year, not a very exact estimate, but we have to do that according to the tax regulations in Sweden. And we are just following what we have to do in Sweden. Good.

Unknown 2
59:05 - 59:38

Then maybe a couple for Anders. And then there was a question here from, uh, Peter. Uh, but I think we've already answered that; it was about the timeline for the evaluation of BAN2802. And I think you already made a statement there. So those were the questions we had online. Um. And I don't think there are any more questions in the telephone queue either. So with that, I guess we can conclude today's call. Thank you, everybody for joining and see you next quarter.

Gunilla Osswald
59:39 - 59:40

Then maybe a couple for Anders.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…